Henrik Kristian Moltke

Fluxome, a Copenhagen-based Danish company, is a recognized leader in the field of industrial biotechnology. Fluxome uses its proprietary, cutting-edge microbial metabolic engineering technology platform to build highly efficient cell factories for the production of a broad range of commercially important nutraceutical ingredients. Fluxome's technology allows the company to rapidly develop and commercialize high purity, natural products manufactured using cost-effective bioprocesses.

EntomoPharm ApS is a holding company that develops insect based absorption, distribution, metabolism, or excretion (ADME) models for early drug discovery. It is a contract research organization that offers validated ex vivo blood brain barrier screening model providing customized study design. Its insect assays can be used to screen small-molecule compounds to identify properties of drug leads in both central nervous system drug development and in safety risk identification for peripherally acting drugs. The firm provides models based on the locust migratory to determine the permeability; the in vivo and the ex vivo model. The company was founded by Peter Aadal Nielsen and Gunnar Andersson in 2009 and is headquartered in Hillerod, Denmark.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark.